PMID- 11164081
OWN - NLM
STAT- MEDLINE
DCOM- 20010419
LR  - 20190712
IS  - 0091-3057 (Print)
IS  - 0091-3057 (Linking)
VI  - 67
IP  - 3
DP  - 2000 Nov
TI  - Effects of prenatal AZT+3TC treatment on open field behavior and responsiveness 
      to scopolamine in adult mice.
PG  - 511-7
AB  - Treatment of pregnant seropositive women and their neonates with the nucleoside 
      analogs (reverse transcriptase inhibitors) zidovudine (AZT), lamivudine (3TC) and 
      their combination has become a standard of care in industrialized countries to 
      prevent transmission of the HIV-1 virus. Animal studies indicated limited but 
      significant behavioral changes in AZT or 3TC-prenatally exposed offspring, 
      whereas data on the potential neurobehavioral outcomes of AZT+3TC combination are 
      still lacking. The aim of the present study was to assess in mice prenatally 
      exposed to AZT+3TC the functional state of cholinergic muscarinic neuroregulation 
      at adulthood. Pregnant CD-1 mice received per orem twice daily AZT+3TC (160 and 
      500 mg/kg, respectively) or vehicle solution (NaCl 0.9%) from gestational day 
      (GD) 10 to delivery (GD 19). Locomotor activity, exploratory behavior and 
      responsiveness to the muscarinic cholinergic blocker scopolamine (2 mg/kg) were 
      analyzed at adulthood (PND 70) in offspring of both sexes in an open field test. 
      Results indicated that prenatal AZT+3TC exposure does not influence 
      responsiveness to the muscarinic cholinergic antagonist as measured by analysis 
      of the drug's effects on locomotor and exploratory activity and different 
      behavioral items. However, AZT+3TC-treated mice displayed higher frequency of 
      rearing, and lower frequency and duration of self-grooming behavior, consistent 
      with an effect on dopaminergic neurotransmission. However, this would need 
      confirmatory experiments.
FAU - Calamandrei, G
AU  - Calamandrei G
AD  - Section of Comparative Psychology, Laboratory of Pathophysiology O.S., Istituto 
      Superiore di Sanita, Viale Regina Elena 299, I-00161, Rome, Italy. gemma@iss.it
FAU - Venerosi, A
AU  - Venerosi A
FAU - Valanzano, A
AU  - Valanzano A
FAU - Alleva, E
AU  - Alleva E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pharmacol Biochem Behav
JT  - Pharmacology, biochemistry, and behavior
JID - 0367050
RN  - 0 (Muscarinic Antagonists)
RN  - 0 (Reverse Transcriptase Inhibitors)
RN  - 2T8Q726O95 (Lamivudine)
RN  - 4B9XT59T7S (Zidovudine)
RN  - DL48G20X8X (Scopolamine)
SB  - IM
MH  - Animals
MH  - Behavior, Animal/*drug effects/physiology
MH  - Female
MH  - Lamivudine/*pharmacology
MH  - Male
MH  - Mice
MH  - Muscarinic Antagonists/*pharmacology
MH  - Pregnancy
MH  - *Prenatal Exposure Delayed Effects
MH  - Reverse Transcriptase Inhibitors/*pharmacology
MH  - Scopolamine/*pharmacology
MH  - Zidovudine/*pharmacology
EDAT- 2001/02/13 11:00
MHDA- 2001/04/21 10:01
CRDT- 2001/02/13 11:00
PHST- 2001/02/13 11:00 [pubmed]
PHST- 2001/04/21 10:01 [medline]
PHST- 2001/02/13 11:00 [entrez]
AID - S0091-3057(00)00386-5 [pii]
AID - 10.1016/s0091-3057(00)00386-5 [doi]
PST - ppublish
SO  - Pharmacol Biochem Behav. 2000 Nov;67(3):511-7. doi: 
      10.1016/s0091-3057(00)00386-5.